MDPI and ACS Style
Gargiulo, L.; Ibba, L.; Malagoli, P.; Amoruso, F.; Argenziano, G.; Balato, A.; Bardazzi, F.; Burlando, M.; Carrera, C.G.; Damiani, G.;
et al. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS). J. Clin. Med. 2024, 13, 495.
https://doi.org/10.3390/jcm13020495
AMA Style
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G,
et al. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of Clinical Medicine. 2024; 13(2):495.
https://doi.org/10.3390/jcm13020495
Chicago/Turabian Style
Gargiulo, Luigi, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani,
and et al. 2024. "Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)" Journal of Clinical Medicine 13, no. 2: 495.
https://doi.org/10.3390/jcm13020495
